These data suggest that pharmacological treatment of AF may be improved by assessing for a defect in the TBX5-SERCA2-PLN axis followed by specifically targeting the defect to restore normal cardiomyocyte electrical activity. The gene discussed is PLN; the disease is atrial fibrillation.